420 with CNW — CBD May Be the Remedy for Gonorrhea and Other Bacterial Diseases
A report from a team of researchers from the University of Australia, published in “Nature,” has demonstrated how synthetic cannabidiol (“CBD”) can eliminate various bacteria responsible for ailments such as Legionnaires’ disease, meningitis and gonorrhea. The report suggests that CBD could bring about a class of new antibiotics for resistant bacteria in a few decades to come.
The researchers tested CBD’s antimicrobial activity using lab models to imitate a two-week patient treatment. This would enable the researchers to observe how rapidly the bacteria mutated to try to outmaneuver cannabidiol’s power to eliminate them. The study’s abstract reported that the researchers discovered that CBD could selectively eliminate a subset of Gram-negative bacteria that included the Neisseria gonorrhea pathogen.
Mark Blaskovich, an associate professor at the university, stated that through a partnership with Botanix Pharmaceuticals, which provided expertise on different formulations, the researchers showed how CBD could penetrate and eliminate various bacteria.
Blaskovich explained that this was the first time a study evaluating how cannabidiol could eliminate certain types of Gram-negative bacteria had been conducted. He continued, stating that the bacteria possessed an additional outer membrane, like an extra line of defense, which made it all the more difficult for antibiotics to infiltrate them.
Blaskovich then mentioned that the researchers hypothesized that CBD eliminated the bacteria by piercing through the outer cell membranes. However, the researchers weren’t sure exactly how CBD did so, citing that they need to conduct further research. He added that cannabidiol had demonstrated a low propensity to create resistance in bacteria.
In addition to this, the researchers also found that the effectiveness of the molecular structure of cannabidiol only changed slightly. Blaskovich noted that this was exciting because it has been decades — since the 1960s — since antibiotics of new molecular classes for Gram-negative infections had been found and approved. Now, he said, researchers could consider developing new cannabidiol analogs in improved properties.
Botanix executive chairman and president Vince Ippolito mentioned in the same statement that the published research demonstrated that synthetic cannabinoids had huge potential as antimicrobials. He then announced that the company was ready to commercialize usable antimicrobial treatments, which he hoped would be accessible to more patients in the future; he noted that the partnership with the university had enabled the company to begin clinical trials on a topical cannabidiol formulation.
Ippolito also added that the clinical results of phase 2a were expected soon, and he hoped that this would open the way for treatments for legionnaires’ disease, meningitis and gonorrhea.
Meanwhile, CBD products have been facing a number of challenges, such as limited shelf life, low bioavailability and poor water solubility. CannAssist International Corp. (OTCQB: CNSC) says it has made improvements regarding those challenges through its line of Xceptol brand products.
NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
A report from a team of researchers from the University of Australia, published in “Nature,” has demonstrated how synthetic cannabidiol (“CBD”) can eliminate various bacteria responsible for ailments such as Legionnaires’ disease, meningitis and gonorrhea. The report suggests that CBD could bring about a class of new antibiotics for resistant bacteria in a few decades to come.
The researchers tested CBD’s antimicrobial activity using lab models to imitate a two-week patient treatment. This would enable the researchers to observe how rapidly the bacteria mutated to try to outmaneuver cannabidiol’s power to eliminate them. The study’s abstract reported that the researchers discovered that CBD could selectively eliminate a subset of Gram-negative bacteria that included the Neisseria gonorrhea pathogen.
Mark Blaskovich, an associate professor at the university, stated that through a partnership with Botanix Pharmaceuticals, which provided expertise on different formulations, the researchers showed how CBD could penetrate and eliminate various bacteria.
Blaskovich explained that this was the first time a study evaluating how cannabidiol could eliminate certain types of Gram-negative bacteria had been conducted. He continued, stating that the bacteria possessed an additional outer membrane, like an extra line of defense, which made it all the more difficult for antibiotics to infiltrate them.
Blaskovich then mentioned that the researchers hypothesized that CBD eliminated the bacteria by piercing through the outer cell membranes. However, the researchers weren’t sure exactly how CBD did so, citing that they need to conduct further research. He added that cannabidiol had demonstrated a low propensity to create resistance in bacteria.
In addition to this, the researchers also found that the effectiveness of the molecular structure of cannabidiol only changed slightly. Blaskovich noted that this was exciting because it has been decades — since the 1960s — since antibiotics of new molecular classes for Gram-negative infections had been found and approved. Now, he said, researchers could consider developing new cannabidiol analogs in improved properties.
Botanix executive chairman and president Vince Ippolito mentioned in the same statement that the published research demonstrated that synthetic cannabinoids had huge potential as antimicrobials. He then announced that the company was ready to commercialize usable antimicrobial treatments, which he hoped would be accessible to more patients in the future; he noted that the partnership with the university had enabled the company to begin clinical trials on a topical cannabidiol formulation.
Ippolito also added that the clinical results of phase 2a were expected soon, and he hoped that this would open the way for treatments for legionnaires’ disease, meningitis and gonorrhea.
Meanwhile, CBD products have been facing a number of challenges, such as limited shelf life, low bioavailability and poor water solubility. CannAssist International Corp. (OTCQB: CNSC) says it has made improvements regarding those challenges through its line of Xceptol brand products.
NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
